Objectives: Granulation tissue is common in otitis media (OM), yet little is known about the signaling pathways in the formation of granulation tissue in response to infections. In this study, we sought to investigate the activation of the transforming growth factor beta (TGF-β) signaling pathway in the formation of granulation tissue in response to middle ear pathogens.
INTRODUCTION
Otitis media (OM) is one of the most common upper respiratory tract infections and is frequently associated with the formation of granulation tissue in the middle ear. The formation of granulation tissue in the middle ear is considered destructive, irreversible, and intractable, and eventually results in the destruction of the ossicular chain and subsequent conductive hearing loss. The pathological characteristics of granulation tissue are the proliferation of new blood vessels in the submucosa and the thickening of the middle ear cleft with active production of extracellular matrix (ECM) proteins. However, little is known about the global gene expression profile of granulation tissue and the molecular signaling pathways involved in the process.
In our early studies, we demonstrated that a transcriptional factor family, inhibitor of differentiation (Id), was up-regulated in the middle ear of rats after bacterial challenges. 1 Id is a product of the transforming growth factor beta (TGF-β) signaling path-way. The fact that the major role of the Id family is to form new blood vessels [2] [3] [4] TGF-β is a pleiotropic cytokine that is produced by many cell types, including inflammatory cells. 5 It is a key regulator of tissue remodeling. [6] [7] [8] [9] [10] [11] TGF-β exerts its effects via a signaling pathway involving receptors (serine/theronine kinases or activin-like receptor kinases [ALKs]) at the cell surface and their substrates, the Smads. 12 Upon phosphorylation and oligomerization, the Smads translocate into the nucleus to regulate the transcription of target genes 13 such as collagen (COL), fibronectin (FN), lami nin (LAM), and tenascin (TN). Through the Smad 14 and mitogen-activated protein kinase (MAPK) pathways, 8 TGF-β regulates the expression of ECMs and early-response oncogenes such as c-fos and c-jun, 7, [15] [16] [17] as well as vascular wall proteins such as smooth muscle α-actin. 18 It is well known that ECM-related and blood vessel-related proteins are involved in the formation of granulation tissue.
The expression of TGF-β isoforms (β1, β2, and β3), TGF-β receptors (types I, II, and III), and TGF-β receptor signaling molecules (Smads and MAPK) under fibrotic disorders is highly regulated. 5, 15, 19, 20 In addition, the T-helper 2 (Th2) cytokines interleukin (IL)-4, IL-5, IL-9, and IL-13 are also involved in submucosal fibrosis. [21] [22] [23] [24] TGF-β1, TGF-β2, and TGF-β3 regulate the production of ECM and stimulate the proliferation of fibroblasts, but inhibit the proliferation of epithelial cells. [25] [26] [27] However, TGF-α exerts an opposite effect, stimulating the proliferation of epithelial cells, but inhibiting the proliferation of fibroblasts. The effects of TGF-β and TGF-α on ECM profiles are distinct. These effects constitute underlying pathologic changes in the mucosal and submucosal layers of the middle ear cleft. To understand the role of major middle ear pathogens in the formation of granulation tissue, we performed global gene expression analysis using microarrays and analyzed the effects of middle ear pathogens on the TGF-β signaling pathway products. The purpose of this study was to explore the disease mechanism through which granulation tissue is formed in OM.
MATERIALS AND METHODS
Eighty-four Sprague-Dawley rats of both sexes were purchased from Charles River Laboratory, Inc (Wilmington, Massachusetts). The Institutional Animal Care and Use Committee approved the use of ani mals in this study. Young and healthy rats, weighing 200 to 225 g, were randomly divided into 12 groups with their bullae challenged with middle ear pathogens (pneumococcus type 6A [Pn6A] or nontypeable Haemophilus influenzae [NTHi]) or eu stachian tube obstruction (ETO) as previous ly described. 28 Each group had 7 animals, and each animal was inoculated with Pn6A (10 6 colony-forming units [cfu]; 50 μL per bulla) and NTHi (10 9 cfu; 50 μL per bulla), which is equivalent to 10 6 cfu of Pn6A in the induction of middle ear inflammation, according to our previous study on the bullae of rats. 29 Bullae with inoculation of the same amount of phosphate-buffered saline solution (PBS; 50 μL per bulla) served as controls. Animals were killed on days 3 and 7. On day 3, middle ear effusion peaked, and on day 7, the effusion was mainly resolved. ETO was performed in 2 groups of rats, as previously described. 29 The rats were killed on days 7 and 30. Sham ETO was performed in 2 additional groups of rats as ETO controls (ie, performance of the ETO surgery without mechanical obstruction of the eustachian tube). After anesthesia with intramuscular injection of keta mine hydrochloride (80 mg/kg) and xylazine hydrochloride (16 mg/kg), both bullae were precisely dissected out at scheduled time points for total RNA extraction and subsequent Affymetrix microarray analysis. At the same time, middle ear tissue sections were made from the above animal models (3 bullae in each group) to examine histopathologic changes, as previously described. 29 Rat middle ear epithelial cells (MEECs) 30 immortalized with temperature-sensitive simian vacuolating virus 40 (SV40), were used to identify genes ex pressed in the epithelial cells. Rat MEEC cultures were maintained in Ham's F-12K medium supplemented with 1.5 g/L sodium bicarbonate, 2.0 mmol/L L-glutamine, 10 ng/mL epidermal growth factor, 10 mg/mL insulin-transferrin-sodium selenite, 2.7 g/L glucose, 500 ng/mL hydrocortisone, 0.1 mmol/L nonessential amino acids, and 4% fetal bovine serum. The media were changed every 3 to 4 days. Cells were cultured at 33°C (permissive temperature, allowing cells to grow) or 39°C (nonpermissive temperature, allowing cells to differentiate) in a 5% carbon dioxide cell culture incubator for the proliferation of MEECs (pMEEC) or the differentiation of MEECs (dMEEC). Approximately 9 to 11 bullae from each group of rats were used for RNA isolation using the Strata-Prep Total RNA Miniprep Kit (Stratagene). Each bulla yielded approximately 3 to 4 μg of total RNA. In each group, approximately 30 to 45 μg of total RNA was used. Affymetrix microarrays were performed, as previously described. 31 Briefly, complementary DNA (cDNA) was prepared from 20 μg total RNA with use of a T7-dT24 primer. Complementary RNA was synthesized from cDNA and biotinylated by means of the BioArray High Yield RNA Transcript Labeling Kit (Enzo Diagnostics, Farmingdale, New York) and hybridized with the Rat U34 arrays (Affymetrix). The intensity of each gene expression in the samples pooled from 9 to 11 bullae is presented as relative light units (RLU). 32 Data presented in this study represent multiple signal molecules related to the TGF-β signaling pathway.
Gene expression intensity that was higher than the background (100 RLU) was included in this study. TGF-β pathway genes were selected from the Affymetrix array data. Because the effector molecules' are controlled by a battery of genes, instead of by a single gene, all of the pathway genes were combined and analyzed by analysis of variance (ANOVA). In consideration of possible positive 
RT-PCR -reverse transcription-polymerase chain reaction; TGF -transforming growth factor. and negative responses from the genes to bacterial challenges, genes up-regulated and down-regulated in the same pathway were grouped together, respectively, and evaluated separately. Differences between controls and experiments were determined by use of a single-factor ANOVA. Transcripts of the genes with significant changes (up-and down-regulated) in the pathway were determined. Next, genes that were up-regulated and down-regulated were evaluated, respectively. Expression changes of multiple genes in the same TGF-β pathway were evaluated with a 2-factor ANOVA with their up-regulated and down-regulated genes evaluated separately. We considered p values of less than 0.05 significant when we weighed differences between experimental and control specimens. In a similar way, we performed microarrays on the rat temperature-sensitive MEECs 30 under proliferating and differentiating conditions (pMEEC and dMEEC) to evaluate gene expression changes in the epithelial cells.
Reverse transcription-polymerase chain reaction (RT-PCR) was performed on total RNA isolated from the middle ear tissue of rats prepared as described above. Specific primers for TGF family genes were designed with Oligo 4.0 and are shown in Table 1 . Sequence information of the TGF-β signaling pathway genes was available at the website of the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov). RT-PCR was performed as described previously 33 Bullae were fixed in 10% paraformaldehyde solution overnight, dehydrated in graded alcohol, immersed in xylene, embedded in paraffin, and cut at a thickness of 4 μm. Sections were deparaffinized in xylene, dehydrated in graded alcohol and then water, and stained with hematoxylin and eosin for histologic analysis, as previously described. 29 Differences of data between the groups were analyzed by nonpaired Student's t-test, ANOVA, or both, with p values of less than 0.05 considered as statistically significant. 
RESULTS
Along the TGF-β signaling pathway, there are many genes, including TGF-β ligands, TGF receptors, Smads, and effectors (Fig 1) . Approximately 26 TGF-β pathway genes altered their expressions (upor down-regulated), and 57 ECM genes (eg, TGF-β pathway effectors) altered after bacterial challenge in the middle ears of the rats. The range of regulation for the TGF-β pathway genes in the experimental groups was between 0.048 and 12.7 times compared with their respective controls ( Table 2) . Because the TGF signaling pathway and its effectors are highly affected by bacterial OM, we focused on the expression profile of the TGF-β signaling pathway in this study.
The Affymetrix microarrays demonstrated that TGF-α was mainly expressed in MEECs, whereas TGF-β1 was mainly in the fibroblasts. TGF-β2 and TGF-β3 were mainly expressed in dMEEC (Fig 2A) . ETO slightly increased the expression of TGF-α, but Pn6A and NTHi did not (Fig 2A; 5th through 9th bars, 1st column). This finding suggests that effusion in the middle ear cavity stimulates the expression of TGF-α. To our surprise, TGF-β1 (mainly expressed in the fibroblasts) was down-regulated in ears with Pn6A and ETO, but was not responsive to NTHi, compared with their controls at the time points studied (Fig 2A; 2nd column) . TGF-β2 was moderately expressed in MEEC, but was weakly expressed in the submucosal layer and was not responsive to Pn6A, NTHi, or ETO (Fig 2A; 3rd column) . TGF-β3 was mainly expressed in pMEEC and was slightly responsive to Pn6A, NTHi, and ETO ( Fig  2A; 4th column) . Genes up-regulated in the TGF-β signaling pathway in middle ear clefts with OM are presented in a heat map ( Fig 2B) .
TGF family members are known to act through type I and type II serine/threonine kinase receptors. There are 7 type I receptors (eg, ALK1-7) and 5 type II receptors (ActRII, ActRIIB, TβRII, BMPRII, and AMHR) in tissues. 14 The TGF receptors expressed in the middle ear cleft were ALK5 (S81584), ALK7 (U69702), ActRII, and ActRIIB. TβRII (M87067) and TβRIII (M80784) were highly expressed in pMEEC, but were weakly expressed in dMEEC. TβRII was slightly up-regulated in bullae with NTHi but less responsive in bullae challenged with Pn6A and ETO. In contrast, TβRIII was moderately expressed in pMEEC, slightly down-regulated in dMEEC, slightly up-regulated at day 3 in bullae with Pn6A infection, and down-regulated in bullae with ETO ( Fig 3) . The expression of the receptors was confirmed by RT-PCR (Table 3 ).
It is known that Smad2 is a downstream molecule for ActRII, ActRIIB, ALK5, and ALK7. 14, 34 The expression of Smad2 (AB017912) was high in pMEEC, but low in dMEEC. Smad2 was up-regulated in Pn6A infection and ETO, but was not changed in NTHi infection. In contrast, the expression of inhibitory Smad7 (AF042499) was relatively low. It was down-regulated in pMEEC, but up-regulated in dMEEC. It was down-regulated in bullae with ETO, and not much changed in Pn6A-and NTHi-infected ears. Smad8 (AF012347) was expressed in the MEECs and tissues at a very low level. The expression of Smads was confirmed by RT-PCR (Table  3) .
There are 57 genes that were recognized as effectors of the TGF-β signaling pathway in this study. These genes include ECMs (COL, TN, FN, and LAM), early-responding genes (c-fos and c-jun), vascular α-actin (essential for angiogenesis), heat shock proteins (chaperones of collagen synthesis such as HSP47), 35 and Th2 ILs (IL-4, IL-5, and IL-13), which are actively involved in submucosal remodeling and fibrotic disorders. 24 Generally speaking, there were both up-and down-regulated expressions of these genes in response to the challenge of Pn6A, NTHi, and ETO in a time-dependent manner. The majority of the genes responded to bacterial OM and ETO with persistently up-or down-regulated expression. There were several genes that responded to bacterial OM with up-or down-regulated expression. However, ETO generally caused downregulated expression of many genes (COL1A1, COL3A1, and FN), whereas NTHi caused up-regulated expression of these genes ( Fig 4A) . On day 3, heat shock proteins (HSP27 and HSP70) were down-regulated in the middle ear cleft after Pn6A and NTHi infections ( Fig 4B) . On day 7, FN3M1 was up-regulated in NTHi infection, but not in Pn6A infection (Fig 4C) . In ETO, FNγ was up-regulated on day 7, whereas FN and COL4A1 were up-regu- Altered expression of TGF-β receptors following challenges of Pn6A, NTHi, and ETO. TGF receptors expressed in MEECs were ActR, ALK7, TβRII (II2), and TβRIII (M80784), whereas those expressed in fibroblasts were III and II2. TβRII (II2) was highly expressed in pMEEC, but was not responsive to Pn6A, NTHi, or ETO. In contrast, TβRIII was moderately expressed in pMEEC, responding to Pn6A, NTHi, and ETO. RLUrelative light units. 
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A lated in ETO on day 30 ( Fig 4D) . The expression of the major effectors was confirmed by RT-PCR ( Table 3 ).
The changes in ECM gene expression were evident. First, fibronectins were highly up-regulated in Pn6Aand NTHi-infected ears on days 3 and 7, as well as in the ears with ETO, on both days 7 and 30. Examination of fibronectins in the MEECs and the entire cleft demonstrated that fibronectins were expressed in both the mucosal and submucosal layers. The major ECMs in response to NTHi infection were COL1A1 and COL3A1 on day 3 (Fig 5A) , and COL3A1 and FN3M1 on day 7 (Fig 5B) . The expression levels of FN-1, TN-C, TN-X, and COL8A1 in dMEEC were higher than those in pMEEC and the middle ear cleft (Fig 5C,D) . Interestingly, COL8A1, TN-C, and laminins were mainly expressed in dMEEC (Fig 5C,D) .
Second, collagens were highly expressed in the middle ear cleft, including types I, II, III, IV, V, VIII, IX, X, XI, and XII (all alpha 1 subunit, except for alpha 3 for type IV). The major collagens in the submucosa (fibroblasts) were types I, III, V, XII, and II, whereas the major collagens in MEECs were VIII, V, XI, and X, in order of messenger RNA (mRNA) abundance. There were 4 genes encoding type 1 alpha 1 (U75405, M27207, z78279, and AF050214, counting for approximately 76% of all collagens in terms of mRNA transcripts) that were significantly up-regulated on day 3 in bullae with NTHi infection (115,483 ± 38,115 RLU) in comparison with find- Altered expression of effectors in TGF-β signaling pathways following challenges of Pn6A, NTHi, and ETO. A) Collagen type I alpha 1 (COL1A1), collagen type III alpha 1 (COL3A1), and fibronectin (FN) were low in MEECs, but were highly expressed in middle ear cleft (panel A) after NTHi at 3 to 7 days, but not Pn6A at 3 to 7 days or ETO at 7 to 30 days. B) Specifically, on day 3, FN1, heat shock protein (HSP) 70, and TGF-β1 were down-regulated in Pn6A-or NTHi-infected ears. C) On day 7, FN3M1 and IL-13 were up-regulated and FN1, HSP70, and TGF-β1 were down-regulated. D) In ears with ETO from 7 to 30 days, COL4A1, COL5A1, FN, FN-1, TGF-β1, and HSP70 were up-or down-regulated.
A ings on day 3 in bullae treated with PBS (77,573 ± 25,656). In contrast, infection with Pn6A on day 3 increased, but did not significantly increase, the expression of COL1A1. COL3A1, which is the second-highest-expressed collagen in the submucosa (accounting for approximately 16% of all collagens in terms of mRNA transcripts), had the same response pattern as COL1A1.
There were remarkably up-and down-regulated genes in bacterial OM or ETO (more than 5 times, compared with their controls). These genes included TGF-β1, receptors, p38MAPK, collagens, and heat shock proteins, which are chaperones of collagen synthesis, tenascins, and fibronectins ( Fig 5) . In Pn6A infection, on days 3 and 7, some collagens and fibronectins were down-regulated, whereas in NTHi infection, on days 3 and 7, collagens and fibronec-tins were up-regulated. In ears with ETO, genes in the TGF-β pathway and effectors had an inclination to be down-regulated.
It is noted that genes up-or down-regulated in ETO are different from those up-and down-regulated in bacterial OM. For example, TGF-α was upregulated in ETO but down-regulated in bacterial OM, whereas TGF-β1 was down-regulated in ETO, but up-regulated in bacterial OM. Smad2, a common mediator for TGF-β1 and TGF-α, was up-regulated in both bacterial OM and ETO. In terms of effectors, NTHi increased the mRNA transcripts (approximately 12% on day 3 and 4% on day 7) for collagens, whereas ETO reduced the mRNA transcripts (approximately 5% on day 7 and 17% on day 30) for collagens. However, with ETO, the expression of COL1A2, COL3A1, COL5A1, COL10A1, COL- , and COL12A1 was reduced, but the expression of COL2A1 and COL4A1 increased, whereas NTHi increased COL1A1, COL3A1, COL8A1, and COL12A1, but reduced COL9A1. Compared with Pn6A, NTHi significantly increased the expression of collagens on day 3.
To verify the formation of granulation tissue, we treated rat bullae with PBS, ETO, Pn6A, and NTHi, respectively, for 14 days and then harvested them for histologic studies. It was found that the PBS-treated middle ear had limited proliferation of fibroblasts in the submucosal layer ( Fig 6A) . Like PBS, ETO caused little or no submucosal response ( Fig 6B) , whereas NTHi caused a remarkable submucosal response ( Fig 6C) . Compared with PBS or ETO, Pn6A caused a moderate response in the submucosal layer of the middle ear cleft ( Fig 6D) . DISCUSSION Granulation tissue is frequently formed during the process of OM. TGF-β plays an important role in the formation of granulation tissue. Recent mouse models for chronic OM support the notion that the TGF-β signaling pathway is involved in this process, 36 although the detailed mechanism is not well understood at the present time.
Granulation tissue formation begins at the acute stage of OM, persists, and accelerates in the chronic stage of OM. It results in proliferation of fibroblasts in the submucosa and thickening of the middle ear cleft. In the chronic stage of OM, proliferation of fibroblasts persists and ECM proteins are continuously deposited to the middle ear submucosa layer, finally leading to fibrosis. In our previous study, we showed that Pn6A induced mucous cell metaplasia of the middle ear mucosa of rats more than NTHi, 29 suggesting that pneumococcus is a potent pathogen that causes OM with mucoid effusion. In this study, we demonstrated that NTHi significantly induced the expression of COL1A1 and COL3A1 during the acute phase (day 3) in comparison with the controls. In contrast, Pn6A induced the expres- sion of collagens to a lesser degree. It was shown in an in vitro study that NTHi activates TβR-Smad3/4 signaling. 37 This suggests that NTHi is a more potent pathogen implicated in granulation tissue and subsequent fibrotic disorders than is Pn6A.
It is well known that TGF-β plays a critical role in fibrotic disorders. 8, 9, 11, 19, 38 In this study, we demonstrated that the TGF pathway activity in ears with bacterial OM was significantly higher than that in controls, suggesting that the pathway was active, although the majority of the genes in this pathway were not dramatically up-regulated at the time studied. To our knowledge, individual genes in this pathway synergistically contribute to the activity of the pathway and lead to fibrotic disorders. Interestingly, the activity of the same pathway was not significantly regulated in ETO. This finding suggests that ETO is not related to the formation of granulation tissue in the middle ear cleft.
Indeed, histologic study of the middle ear mucosa with bacterial OM revealed that submucosal responses are obvious, whereas the ears with ETO revealed little or no submucosal thickening. It should be noted that when a single gene was selected for analysis, it was difficult to reflect the entire pathway activity: individual genes may be down-regulated while the entire pathway activity is actually up-regulated. For example, TGF-β1 is an important member of the TGF family involved in fibrotic disorders, but it was not up-regulated in Pn6A-infected middle ears. Instead, TGF-β1 was up-regulated in NTHi-infected middle ears on day 3. However, when TGF-β2, TGF-β3, and their receptors and subsequent molecules, such as Smads, were combined together, the changes were significant. The TGF family genes are in part up-regulated and in part down-regulated. By means of microarray data analysis, it is becoming clear that the TGF-β signaling pathway, as a whole, 212 Lee et al, Transforming Growth Factor Beta in Otitis Media 212 is up-regulated -although the regulation of individual genes at the ligand or receptor level may not be so at the time studied. Interestingly, TGF-β (especially TGF-β2 and TGF-β3) and its receptors (TβRII) are highly expressed in MEECs -a finding that suggests that the TGF signaling pathway begins at the epithelial layer and then disseminates to the submucosal layer.
In addition to TGF-β, T-helper cells that produce cytokines, such as IL-4, IL-5, and IL-13, may be involved in the process of fibrotic disorders, because those cytokines are highly up-regulated. The fibrotic disorders then result in the hyperproduction of COL1A1 and COL3A1. we know that TGF-β is involved in tissue remodeling of the middle ear mucosa, but we do not know which TGF-β members are involved in this process or how it occurs. In this study, we demonstrate that TGF-β1, mainly expressed in fibroblasts, and TGF-β2 and TGF-β3, mainly expressed in the MEECs, are all involved in the inflammatory response of the middle ear cleft.
As shown in our previous studies, bacterial OM leads to up-regulation of the Id family, Id1, and Id3, 1 which are potential triggers for the development of new blood vessels. In this study, bacterial OM increased the production of ECMs. This constitutes a pathological basis for the formation of granulation tissue in the middle ear cleft.
To summarize, the expression of ECM mRNA transcripts (COL1A1, COL3A1, COL5A1, etc) and major collagens in the middle ear cleft was reduced in ETO. The expression of those ECM mRNA transcripts increased in bacterial OM, especially that caused by NTHi. Since COL1A1, COL3A1, and COL5A1 count for approximately 90% of collagen mRNA transcripts, it is plausible to assume that bacteria, especially NTHi, are potent triggers for the formation of granulation tissue.
